Lipoprotein Apheresis

Patrick M Moriarty; Linda Hemphill

doi:10.1016/j.ecl.2015.09.003

Lipoprotein Apheresis

Endocrinol Metab Clin North Am. 2016 Mar;45(1):39-54. doi: 10.1016/j.ecl.2015.09.003.

Authors

Patrick M Moriarty¹, Linda Hemphill²

Affiliations

¹ Division of Clinical Pharmacology and Atherosclerosis/Lipoprotein-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3008, Kansas City, KS 66160, USA. Electronic address: [email protected].
² Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.

PMID: 26892996
DOI: 10.1016/j.ecl.2015.09.003

Abstract

Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients with FH with hypercholesterolemia. LA reduces LDL-C levels by more than 60% in patients with FH and reduces CVD events. LA also reduces Lp(a) levels and CVD events. LA reduces inflammatory markers and blood viscosity.

Keywords: Atherosclerosis; CVD; Familial hypercholesterolemia; LDL-C; Lipoprotein apheresis; Lp(a).

Publication types

Review